Clinical Trials
June 2010

Comparison of Natamycin and Voriconazole for the Treatment of Fungal Keratitis

Author Affiliations

Author Affiliations: Aravind Eye Care System, Madurai, India (Drs N. V. Prajna, Mascarenhas, L. Prajna, and Srinivasan); Aravind Eye Care System, Pondicherry, India (Drs Krishnan and Reddy, and Mr Vaitilingam); F.I. Proctor Foundation (Drs Lee, McLeod, Porco, Lietman, and Acharya, and Mr Hong), Departments of Ophthalmology (Drs McLeod, Lietman, and Acharya) and Epidemiology and Biostatistics (Drs Porco and Lietman), and the Institute for Global Health (Dr Lietman), University of California, San Francisco; Departments of Surgery (Ophthalmology) and Microbiology and Immunology (Dr Zegans), Dartmouth Medical School, Lebanon, New Hampshire.




Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2010

Arch Ophthalmol. 2010;128(6):672-678. doi:10.1001/archophthalmol.2010.102

Objective  To conduct a therapeutic exploratory clinical trial comparing clinical outcomes of treatment with topical natamycin vs topical voriconazole for fungal keratitis.

Methods  The multicenter, double-masked, clinical trial included 120 patients with fungal keratitis at Aravind Eye Hospital in India who were randomized to receive either topical natamycin or topical voriconazole and either had repeated scraping of the epithelium or not.

Main Outcome Measures  The primary outcome was best spectacle-corrected visual acuity (BSCVA) at 3 months. Other outcomes included scar size, perforations, and a subanalysis of BSCVA at 3 months in patients with an enrollment visual acuity of 20/40 to 20/400.

Results  Compared with those who received natamycin, voriconazole-treated patients had an approximately 1-line improvement in BSCVA at 3 months after adjusting for scraping in a multivariate regression model but the difference was not statistically significant (P = .29). Scar size at 3 months was slightly greater with voriconazole after adjusting for scraping (P = .48). Corneal perforations in the voriconazole group (10 of 60 patients) were not significantly different than in the natamycin-treated group (9 of 60 patients) (P >.99). Scraping was associated with worse BSCVA at 3 months after adjusting for drug (P = .06). Patients with baseline BSCVA of 20/40 to 20/400 showed a trend toward a 2-line improvement in visual acuity with voriconazole (P = .07).

Conclusions  Overall, there were no significant differences in visual acuity, scar size, and perforations between voriconazole- and natamycin-treated patients. There was a trend toward scraping being associated with worse outcomes.

Application to Clinical Practice  The benefit seen with voriconazole in the subgroup of patients with baseline visual acuity of 20/40 to 20/400 needs to be validated in a confirmatory clinical trial.

Trial Registration Identifier: NCT00557362